MX2021010544A - Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos. - Google Patents

Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.

Info

Publication number
MX2021010544A
MX2021010544A MX2021010544A MX2021010544A MX2021010544A MX 2021010544 A MX2021010544 A MX 2021010544A MX 2021010544 A MX2021010544 A MX 2021010544A MX 2021010544 A MX2021010544 A MX 2021010544A MX 2021010544 A MX2021010544 A MX 2021010544A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
receptor type
Prior art date
Application number
MX2021010544A
Other languages
English (en)
Inventor
Mark A Matulenko
Andrew Bogdan
Jennifer M Frost
Philip R Kym
Eric Voight
Geoff T Halvorsen
Zhaoming Xiong
Qingwei I Zhang
Christina Baumgartner
Christos Economou
Elliot P Farney
Matthew O''connor
Reza Shiroodi
Jason Abbott
Stacy Fosu
Original Assignee
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc filed Critical Calico Life Sciences Llc
Publication of MX2021010544A publication Critical patent/MX2021010544A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos útiles para la inhibición de la proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora tipo 1 (PTPN1), y para el tratamiento de enfermedades, trastornos y afecciones relacionadas que responden favorablemente al tratamiento con un inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
MX2021010544A 2019-03-14 2020-03-13 Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos. MX2021010544A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818447P 2019-03-14 2019-03-14
PCT/US2020/022717 WO2020186199A1 (en) 2019-03-14 2020-03-13 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021010544A true MX2021010544A (es) 2021-10-01

Family

ID=70190226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010544A MX2021010544A (es) 2019-03-14 2020-03-13 Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.

Country Status (22)

Country Link
US (1) US10851073B2 (es)
EP (1) EP3938038A1 (es)
JP (2) JP7204005B2 (es)
KR (2) KR102533599B1 (es)
CN (2) CN114025844B (es)
AR (1) AR118374A1 (es)
AU (1) AU2020234712A1 (es)
BR (1) BR112021017430A2 (es)
CA (1) CA3131894A1 (es)
CL (1) CL2021002382A1 (es)
CO (1) CO2021013524A2 (es)
CR (1) CR20210516A (es)
DO (1) DOP2021000188A (es)
EC (1) ECSP21075909A (es)
IL (1) IL286373A (es)
MA (1) MA55301A (es)
MX (1) MX2021010544A (es)
PE (1) PE20212154A1 (es)
SG (1) SG11202109067PA (es)
TW (1) TW202100515A (es)
UY (1) UY38613A (es)
WO (1) WO2020186199A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4077291A1 (en) * 2019-12-18 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof
JP2023542503A (ja) * 2020-09-11 2023-10-10 カリコ ライフ サイエンシーズ エルエルシー タンパク質チロシンホスファターゼ阻害物質及びその使用方法
US20240174631A1 (en) * 2021-02-12 2024-05-30 Recovery Therapeutics, Inc. Compounds, compositions, and methods for modulating fgf activity
EP4305030A1 (en) * 2021-03-11 2024-01-17 Kumquat Biosciences Inc. Heterocycles and uses thereof
WO2022261145A1 (en) * 2021-06-10 2022-12-15 Ness Therapeutics, Inc. Compounds having 5-(2-fluoro-6-hydroxyphenyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide as inhibitors of protein kinase phosphatase enzymes
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023086495A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2023150150A1 (en) * 2022-02-02 2023-08-10 Nerio Therapeutics, Inc. Protein tyrosine phosphatase inhibitors and uses thereof
TW202342437A (zh) * 2022-02-02 2023-11-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
TW202337459A (zh) * 2022-02-02 2023-10-01 美商耐瑞歐醫療公司 蛋白酪胺酸磷酸酶抑制劑及其用途
WO2023179542A1 (en) * 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof
WO2024067802A1 (zh) * 2022-09-30 2024-04-04 深圳众格生物科技有限公司 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IL161582A0 (en) 2001-10-30 2004-09-27 Applied Research Systems Use of oxindole hydrazide derivatives for the preparation of pharmaceutical compositions, certain such new derivatives and their preparation
UA94724C2 (en) * 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
KR20080110882A (ko) * 2006-03-31 2008-12-19 노파르티스 아게 ＰＴＰａｓｅ의 티아디아졸리디논 억제제
WO2008142198A2 (en) 2007-05-23 2008-11-27 Valtion Teknillinen Tutkimuskeskus A method for inhibiting or stimulating angiogenesis in an individual
AR066820A1 (es) * 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2010008852A2 (en) 2008-06-23 2010-01-21 Taiga Biotechnologies, Inc. Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder
WO2010118241A2 (en) 2009-04-08 2010-10-14 Indiana University Research & Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2011057331A1 (en) 2009-11-11 2011-05-19 Monash University A method for treating obesity
US20130202577A1 (en) 2010-02-03 2013-08-08 Monash University Diagnostic and prognostic assay for breast cancer
EP3110824A4 (en) 2014-02-28 2017-11-29 The Royal Institution for the Advancement of Learning / McGill University Tc-ptp inhibitors as apc activators for immunotherapy
US20170224731A1 (en) 2014-06-10 2017-08-10 Monash University Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
WO2017078499A2 (ko) 2015-11-06 2017-05-11 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
US20180325925A1 (en) 2015-11-06 2018-11-15 Kyungpook National University Industry-Academic Cooperation Foundation Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2018148378A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2018227248A1 (en) 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
US11597739B2 (en) 2017-08-24 2023-03-07 The Royal Institution For The Advancement Of Learning/Mcgill University Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP)
MX2020014223A (es) * 2018-06-21 2021-06-23 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y sus metodos de uso.

Also Published As

Publication number Publication date
CN116332873A (zh) 2023-06-27
DOP2021000188A (es) 2022-03-15
CN114025844B (zh) 2022-07-26
ECSP21075909A (es) 2021-11-30
JP7204005B2 (ja) 2023-01-13
CN114025844A (zh) 2022-02-08
AR118374A1 (es) 2021-09-29
AU2020234712A1 (en) 2021-09-09
KR20230074822A (ko) 2023-05-31
US10851073B2 (en) 2020-12-01
KR20210151821A (ko) 2021-12-14
MA55301A (fr) 2022-01-19
UY38613A (es) 2020-09-30
TW202100515A (zh) 2021-01-01
IL286373A (en) 2021-10-31
EP3938038A1 (en) 2022-01-19
CL2021002382A1 (es) 2022-06-03
CO2021013524A2 (es) 2022-02-28
KR102533599B1 (ko) 2023-05-17
PE20212154A1 (es) 2021-11-09
JP2022522526A (ja) 2022-04-19
BR112021017430A2 (pt) 2022-01-18
JP2023052094A (ja) 2023-04-11
WO2020186199A1 (en) 2020-09-17
CR20210516A (es) 2022-07-19
CA3131894A1 (en) 2020-09-17
SG11202109067PA (en) 2021-09-29
US20200299246A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CR20210516A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
MX2022001302A (es) Inhibidores de kif18a.
MX2022001181A (es) Inhibidores de kif18a.
MX2023011576A (es) Compuestos para la inhibicion de proteinas que contienen el dominio de pirina de la familia nlr 3 (nlrp3) y usos de estos.
EA202091709A1 (ru) Ингибиторы днк-пк
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
EA202191422A1 (ru) Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
EA202091708A1 (ru) Ингибиторы днк-пк
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
MX2022002443A (es) Compuestos inhibidores de perk.
MX2021010829A (es) Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb).
EA202190125A1 (ru) ПРОИЗВОДНЫЕ ПИРИДОПИРИМИДИНОНА ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Axl
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
EA202190112A1 (ru) Ингибирование creb-связывающего белка (cbp)
EA202191523A1 (ru) Способы лечения видов рака, при которых сверхэкспрессируется whsc1, путем ингибирования активности setd2
EA202092449A1 (ru) ИНГИБИТОРЫ Bcl-2
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak